220 related articles for article (PubMed ID: 31053626)
1. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response.
Gandhapudi SK; Ward M; Bush JPC; Bedu-Addo F; Conn G; Woodward JG
J Immunol; 2019 Jun; 202(12):3524-3536. PubMed ID: 31053626
[TBL] [Abstract][Full Text] [Related]
2. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine.
Vasievich EA; Chen W; Huang L
Cancer Immunol Immunother; 2011 May; 60(5):629-38. PubMed ID: 21267720
[TBL] [Abstract][Full Text] [Related]
3. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.
Vasievich EA; Ramishetti S; Zhang Y; Huang L
Mol Pharm; 2012 Feb; 9(2):261-8. PubMed ID: 22142394
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
5. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid.
Chen W; Yan W; Huang L
Cancer Immunol Immunother; 2008 Apr; 57(4):517-30. PubMed ID: 17724588
[TBL] [Abstract][Full Text] [Related]
6. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
[TBL] [Abstract][Full Text] [Related]
8. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
[TBL] [Abstract][Full Text] [Related]
9. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
10. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
11. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine.
Chen W; Huang L
Mol Pharm; 2008; 5(3):464-71. PubMed ID: 18266319
[TBL] [Abstract][Full Text] [Related]
12. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.
Asprodites N; Zheng L; Geng D; Velasco-Gonzalez C; Sanchez-Perez L; Davila E
FASEB J; 2008 Oct; 22(10):3628-37. PubMed ID: 18587008
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.
Jung ID; Shin SJ; Lee MG; Kang TH; Han HD; Lee SJ; Kim WS; Kim HM; Park WS; Kim HW; Yun CH; Lee EK; Wu TC; Park YM
J Immunol; 2014 Aug; 193(3):1233-45. PubMed ID: 24990079
[TBL] [Abstract][Full Text] [Related]
14. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.
Yan W; Huang L
Int J Pharm; 2009 Feb; 368(1-2):56-62. PubMed ID: 18992312
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine.
Yan W; Chen W; Huang L
J Control Release; 2008 Aug; 130(1):22-8. PubMed ID: 18554742
[TBL] [Abstract][Full Text] [Related]
17. Targeted nanoparticles deliver siRNA to melanoma.
Chen Y; Bathula SR; Yang Q; Huang L
J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
[TBL] [Abstract][Full Text] [Related]
18. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse interleukin 27 by means of cationic liposome.
Zhang J; Tian H; Li C; Cheng L; Zhang S; Zhang X; Wang R; Xu F; Dai L; Shi G; Chen X; Li Y; Du T; Deng J; Liu Y; Yang Y; Wei Y; Deng H
Mol Immunol; 2013 Oct; 55(3-4):264-74. PubMed ID: 23522926
[TBL] [Abstract][Full Text] [Related]
20. L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.
Watson HA; Durairaj RRP; Ohme J; Alatsatianos M; Almutairi H; Mohammed RN; Vigar M; Reed SG; Paisey SJ; Marshall C; Gallimore A; Ager A
Front Immunol; 2019; 10():1321. PubMed ID: 31249570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
